GCTK
GlucoTrack, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · IL
$2.98
−10.24%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 43.0K | — | — | — | — |
| Gross Profit | (43.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 8.9M | 9.8M | 9.5M | 4.7M | 2.0M |
| SG&A Expense | 6.5M | 6.3M | 5.0M | 2.4M | 2.5M |
| General & Admin Expense | 6.8M | 6.3M | 4.7M | 2.3M | 2.5M |
| Selling & Marketing Expense | (310.0K) | — | 393.0K | 122.0K | — |
| Other Expenses | (8.7M) | — | — | 3.0K | 11.0K |
| Total Operating Expenses | 6.7M | 16.1M | 14.5M | 7.1M | 4.4M |
| Cost and Expenses | 6.8M | 16.1M | 14.5M | 7.1M | 4.4M |
| Operating Income (EBIT) | (6.8M) | (16.1M) | (14.5M) | (7.1M) | (4.4M) |
| Non-Operating | |||||
| Interest Income | — | — | 62.0K | 7.0K | 11.0K |
| Interest Expense | 125.0K | — | 628.0K | — | 3.0K |
| Net Interest Income | (125.0K) | — | (566.0K) | 7.0K | 8.0K |
| Other Non-Op Income/Expense | (9.2M) | (3.3M) | (8.1M) | 7.0K | (3.0K) |
| Non-Operating Income (excl Interest) | 9.3M | 3.3M | 7.4M | (7.0K) | — |
| EBT (Pre-Tax Income) | (15.9M) | (19.4M) | (22.6M) | (7.1M) | (4.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (15.9M) | (19.4M) | (22.6M) | (7.1M) | (4.4M) |
| Earnings from Cont. Ops | (15.9M) | (19.4M) | (22.6M) | (7.1M) | (4.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (15.9M) | (19.4M) | (22.6M) | (8.0M) | (4.4M) |
| Per Share | |||||
| Basic EPS | ($180.45) | ($323.40) | ($911.40) | ($574.50) | ($429.90) |
| Diluted EPS | ($180.45) | ($323.40) | ($911.40) | ($574.50) | ($429.90) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 222194 | 59961 | 24794 | 12333 | 10267 |
| Diluted Shares Outstanding | 222194 | 59961 | 24794 | 13840 | 10316 |
| Profitability Metrics | |||||
| EBITDA | (16.0M) | (19.3M) | (21.9M) | (7.1M) | (4.4M) |
| D&A | 66.0K | 42.0K | 36.0K | 13.0K | 23.0K |
| EBIT | (16.1M) | (19.4M) | (22.0M) | (7.1M) | (4.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026